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Abstract
Introduction: Alcohol dependence is one of the most com-
mon substance use disorders, and novel treatment options 
are urgently needed. Neurofeedback training (NFT) based 
on real-time functional magnetic resonance imaging (rtf-
MRI) has emerged as an attractive candidate for add-on 
treatments in psychiatry, but its use in alcohol dependence 
has not been formally investigated in a clinical trial. We in-
vestigated the use of rtfMRI-based NFT to prevent relapse in 
alcohol dependence. Methods: Fifty-two alcohol-depen-
dent patients from the UK who had completed a detoxifica-
tion program were randomly assigned to a treatment group 
(receiving rtfMRI NFT in addition to standard care) or the 
control group (receiving standard care only). At baseline, al-
cohol consumption was assessed as the primary outcome 
measure and a variety of psychological, behavioral, and neu-
ral parameters as secondary outcome measures to deter-
mine feasibility and secondary training effects. Participants 
in the treatment group underwent 6 NFT sessions over 4 
months and were trained to downregulate their brain activa-
tion in the salience network in the presence of alcohol stim-
uli and to upregulate frontal activation in response to pic-
tures related to positive goals. Four, 8, and 12 months after 
baseline assessment, both groups were followed up with a 
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battery of clinical and psychometric tests. Results: Primary 
outcome measures showed very low relapse rates for both 
groups. Analysis of neural secondary outcome measures in-
dicated that the majority of patients modulated the salience 
system in the desired directions, by decreasing activity in re-
sponse to alcohol stimuli and increasing activation in re-
sponse to positive goals. The intervention had a good safety 
and acceptability profile. Conclusion: We demonstrated that 
rtfMRI-neurofeedback targeting hyperactivity of the sa-
lience network in response to alcohol cues is feasible in cur-
rently abstinent patients with alcohol dependence.
© 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Neurofeedback, a type of biofeedback that utilizes 
brain signals for self-regulation training, has seen a recent 
rise in clinical interest because of the development of real-
time functional magnetic resonance imaging (rtfMRI). 
For neurofeedback training (NFT), rtfMRI offers benefits 
when compared to EEG neurofeedback. For example, 
fMRI can be used to localize brain signals in specific re-
gions of the brain with greater precision, and patients can 
activate targeted brain areas by using specific mental im-
agery (e.g., imagining moving a body part). In pilot inves-
tigations, rtfMRI NFT has already been tested for its po-
tential to help patients with various kinds of substance use 
disorder to attenuate their symptoms, reduce the fre-
quency or intensity of their unwanted behavior, and/or 
modulate putative disease-related brain activity [1–5].
We conducted an early-phase randomized controlled 
trial for alcohol dependence, in which we compared NFT 
plus treatment-as-usual (TAU) versus TAU only [6]. Par-
ticipants in the neurofeedback group were exposed to 2 
categories of stimuli while they were in the scanner. One 
category comprised alcohol-related pictures, such as im-
ages of alcoholic drinks. The other category comprised 
pictures that were related to socially desirable and healthy 
goals (those related to, e.g., employment, family, or per-
sonal relationships) whose pursuit might serve as an al-
ternative to drinking alcohol. Participants received feed-
back about the degree of activation in specific brain re-
gions that the stimuli in each category activated, and they 
were trained to regulate these responses – either to down-
regulate their responses to the alcohol-related stimuli or 
to upregulate their responses to the alternative goal stim-
uli. The inclusion of both alcohol-related and alternative 
goal-related stimuli was consistent with motivational the-
ory [7–9], which has shown that problematic drinkers are 
better able to regulate their drinking if they have healthy, 
alternative goals to pursue. For testing this tenet of moti-
vational theory, we had also previously shown that at a 
neural level, heavy drinkers overvalue alcohol and under-
value other goals that they might pursue and enjoy as an 
alternative to drinking alcohol [10]. The objectives of this 
early-phase randomized controlled trial were to deter-
mine (a) the feasibility of the approach, that is, whether 
participants who received rtfMRI NFT would be able to 
downregulate their brain activation in the presence of the 
alcohol-related stimuli and to upregulate their brain acti-
vation in the presence of the alternative goal-related stim-
uli and (b) whether the training would be associated with 
changes on our primary outcome measures, that is, re-
ductions in alcohol consumption, reductions in urges to 
drink, and with improvements in other areas of function-
ing (efficacy).
Materials and Methods
Patients, Eligibility, and Randomization
Fifty-two participants with alcohol dependence were recruited 
from 2015 to 2017 through NHS alcohol services in southeast 
Wales (Cardiff and Vale University Health Board, Cwm Taf Uni-
versity Health Board, and Aneurin Bevan University Health 
Board) with the help of collaborating clinicians specializing in ad-
diction, staff from the Health and Care Research Wales Clinical 
Research Centre and through alcohol addiction rehabilitation cen-
ters.
Participants were eligible to take part in the study if they were 
older than 18 years, had a clinical diagnosis of alcohol dependence, 
were within 1–6 months of having successfully completed an in-
patient detoxification program, and had been abstinent from alco-
hol use since detoxification and at the time of recruitment. The 
exclusion criteria were ongoing regular abuse of illicit substances 
(except for cannabis), a history of a psychotic disorder not related 
to alcohol, an IQ < 70, involvement in other interventional re-
search within the 6 months prior to recruitment, and non-fulfill-
ment of the MRI safety requirements.
Randomization was carried out through an online system over-
seen by the Centre for Trials Research, Cardiff University. Partici-
pants were randomized into either the neurofeedback treatment 
(NFT) group or the TAU group. The randomization method used 
time since detoxification (1–3 months and 4–6 months) as a min-
imization factor.
Standard Protocol Approval, Registration, and Patient Consent
This study was approved by the Wales Research Ethics Com-
mittee 1 (Ref: 14/WA/1172), the Cardiff School of Psychology Eth-
ics Committee, and the Cwm Taf, Cardiff and Vale University, and 
Aneurin Bevan University Health Boards. All participants gave 
written informed consent to participate in the study in accordance 
with the Declaration of Helsinki. The trial was registered with 
Clinicaltrials.gov (NCT02486900) in June 2015 before the first 




participant was recruited. The study was completed in August 
2018 after acquisition of the final follow-up assessments.
Design
Fifty-two patients were randomly allocated (parallel assign-
ment) to receive either the neurofeedback intervention along with 
TAU NFT group or TAU control group. TAU included psycho-
education, psychological support, and medical management of ab-
stinence with, for example, the use of disulfiram or anti-craving 
medication. After completing the study, patients in the control 
group were offered 1 free NFT session. The NFT group received 
six 1-h sessions of NFT. The study was completed in August 2018 
after acquisition of the final follow-up assessments. Figure 1 shows 
a flowchart of the study procedure.
Psychological and Behavioral Outcome Measures
At all 4 time points, the clinical outcome measure of alcohol 
consumption, the Alcohol Timeline Followback (TLFB [11]), was 
assessed and constituted the primary outcome measure at the 
4-month time point and a secondary outcome measure at subse-
quent time points. All other secondary outcome measures were 
also acquired at all 4 time points, that is, for craving-related con-
structs, the Drinking Urge Questionnaire (DUQ [12]), the Obses-
sive Compulsive Drinking Scale (OCDS [13]), and alcohol Stroop 
test [14], and for emotion/mood-related processes, the Profile of 
Mood States (POMS [15]), the Hospital Anxiety and Depression 
Scale (HADS) [16], and Beck Depression Inventory (BDI-II [17]). 
Additionally, in the NFT group, alcohol craving was measured 
during the MRI session as a safety measure, that is, to track wheth-
er the images would induce craving. Ratings on a 5-point self-rat-
ing scale (0: no desire to drink alcohol; 4: very strong desire) were 
acquired for each of the neurofeedback/mirror runs in each ses-
sion. Furthermore, participants self-rated their craving before and 
after each neurofeedback session by using the DUQ [12]. (For 
screening and overall baseline assessments, see [12].)
NFT Protocol for the NFT Group
During the baseline assessment, participants rated the alcohol-
related pictures, in relation to how much each picture made them 
want to drink alcohol. For the pictures related to alternative goals, 
participants indicated how much each one reminded them of a 
positive goal that they were currently pursuing. Based on these rat-
ings, individual images were selected for the localizer task (see [6] 
for details). Patients in the NFT group subsequently received six 
1-h sessions of NFT in the MRI scanner (see [6]). In short, the first 
run of each session served as the localizer procedure in which al-
ternating blocks of neutral pictures and either alcohol-related pic-
tures or alternative goal-related pictures, were presented to the 
participants. Brain clusters activated during presentation of the 
alcohol/goal-related pictures in comparison to those activated by 
the neutral images were used to create individual neurofeedback 
regions for the subsequent neurofeedback runs (SI). The 4 scan-
ning blocks (runs) that followed consisted of 2 neurofeedback and 
2 mirror runs in alternating order. Neurofeedback was provided 
by scaling the size of the pictures presented according to the ROI 
signal (see fMRI data acquisition and feedback generation), which 
participants attempted to decrease while seeing the alcohol pic-
tures and to increase while seeing the pictures related to alternative 
goals. During the mirror runs, participants passively viewed the 
stimuli, and the size of the image changed in accordance with the 
previous neurofeedback run and did not contain any information 
about their current level of brain activation.
During alcohol runs (neurofeedback and mirror runs), partici-
pants were instructed to downregulate their brain activity (using 
mental imagery) in the alcohol-related brain areas by decreasing 
the size of the alcohol-related images. Participants were instructed 
to think of ways to reduce the size of the images, and they were 
given continuous feedback about their brain activity in the target 
region. During the alternative goal-related runs, participants were 
instructed to upregulate brain activity in the target region (chosen 
for each individual while they viewed pictures related to positive 
personal goals).
After each session, participants were debriefed about their ex-
perience and given the opportunity to raise any concerns about 
their craving or other adverse effects of the procedure for which 
counseling would have been available. This however was never re-
quired. Once participants had identified their individual strategies 
(i.e., the strategy that they subjectively judged as being most suited) 
for decreasing the size of the alcohol-related pictures or for in-
creasing the size of the pictures related to their alternative goals, 
they were asked as homework to spend 10 min 2–3 times a week 
using the imagining strategies that worked best.
fMRI Data Acquisition and Feedback Generation
The Siemens and GE MRI scanners at the Cardiff University 
Brain Research Imaging Centre were used to acquire the func-
tional and anatomical scans. A high-resolution T1-weighted ana-
tomical scan (24 slices) was acquired. Functional data were ob-
tained using a standard BOLD EPI sequence (TR = 1,500 ms; 
TE = 30 ms, 24 slices; 2.5 mm thick; 0.5 mm gap; 80 flip angle). A 
total of 300 volumes were acquired in each functional run for each 
participant. Acquired EPI data were transferred to a separate 
computer, which in real-time ran Turbo-BrainVoyager (version 
3.2, Brain Innovation, Maastricht, The Netherlands) and was used 
to perform real-time trilinear motion correction and spatial 
smoothing (FWHM 4 mm) and linear trend removal. For the lo-
calizer scan, real-time statistical analyses were carried out via an 
incremental general linear model (GLM). All further real-time 
analyses were performed using Turbo-BrainVoyager. Based on 
the computed feedback signal, the size of presented images was 
scaled (see [6] for details) using StimulGL. To control for physi-
ological confounding factors of the BOLD signal (offline), physi-
ological signals were acquired with Spike2 (version 5.21, Cam-
bridge Electronics Design Ltd., Cambridge, UK). The heart rate 
was also recorded using photoplethysmography, the respiratory 
rate with a chest belt, and partial pressure of end-tidal carbon di-
oxide (PETCO2) via a nasal cannula.
Sample Size Calculation
There were no published randomized trials to inform a sample 
size calculation for the early-phase efficacy trial of the neurofeed-
back intervention that was being evaluated. However, experimen-
tal neurofeedback studies have found large effect sizes of 0.5–1.5, 
depending on the patient group that was tested, for example [2]. 
Thus, in the prespecified power analysis [6], we expected that a 
final sample size of 40 (20 in each group) would allow us to detect 
effect sizes ranging from 0.8 with 70% power to 1.1 with 90% pow-
er at a significance level of 0.05. This is appropriate for single-site, 
early-phase detection of clinically promising results.
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Allocated to intervention (n = 25)
• Received allocated intervention (n = 20)
• Did not receive allocated
intervention (n = 5) (not able to
commit to study time requirements)
Discontinued intervention (n = 4 ):
1: work commitments, 2: no reason
given, 1: family problems
Lost to follow-up (n = 7): not able to
contact
Follow-up
Allocated to treatment as usual
(n = 27)
Excluded (n = 45)
• Not meeting inclusion criteria (n = 15)
• Declined to participate (n = 9)








Assessed for objective 1 (n = 16):
primary outcome measure
Assessed for objective 2 (n = 16),
secondary outcome measure
Assessed for objective 1 (n = 14):
primary outcome measure
Assessed for objective 2 (n = 13),
secondary outcome measure
Not able to contact: n = 2
Assessed for objective 1 (n = 12):
primary outcome measure
Assessed for objective 2 (n = 12),
secondary outcome measure
Not able to contact: n = 4
4 month assessment:
Analysed for objective 1 and 2: n = 16
8 month assessment:
Analysed for objective 1: n = 14
Analysed for objective 2: n = 13
12 month assessment:
Analysed for objective 1: n = 12
Analysed for objective 2: n = 12
4 month assessment:
Analysed for objective 1 and 2: n = 18
Incomplete data: n = 2
8 month assessment:
Analysed for objective 1: n = 14
Analysed for objective 2: n = 14
12 month assessment:
Analysed for objective 1: n = 13
Analysed for objective 2: n = 14
Assessed for objective 1 (n = 13):
primary outcome measure
Assessed for objective 2 (n = 14),
secondary outcome measure
Not able to contact: n = 6
Assessed for objective 1 (n = 14):
primary outcome measure
Assessed for objective 2 (n = 14 ),
secondary outcome measure
Not able to contact: n = 6
Assessed for objective 1 (n = 20):
primary outcome measure
Assessed for objective 2 (n = 19),
secondary outcome measure
Fig. 1. CONSORT flow diagram of the 
phases of the trial. TAU, treatment-as-usu-
al; CONSORT, Consolidated Standards of 
Reporting Trials.





The research questions, analyses, and hypotheses of 
this trial were previously published [6].
Psychological Markers
Primary Outcome Measures
Fifty percent of the participants were abstinent from 
alcohol during the entire post-intervention period. TLFB 
scores were therefore dichotomized. On the basis of alco-
hol units per day, the sample was divided into participants 
who had not drunk at all and those who had one or more 
drinks per day. On the basis of % days of heavy drinking, 
the sample was divided into participants who had been 
totally abstinent and those who had not been abstinent 
and accordingly for the % days abstinent scale. Subse-
quently, a binary logistic regression model was run that 
included group as a predictor variable and time since de-
toxification as the covariate, separately for each TLFB 
variable.
Secondary Outcome Measures
ANCOVAs were conducted for the post-intervention, 
4-month follow-up on the secondary outcome measures: 
HADS, BDI, OCDS, alcohol Stroop, and POMS. The type 
of treatment (NFT and TAU) was the between-group fac-
tor, and the baseline scores on the respective variable and 
participants’ age, gender, and IQ were the covariates. For 
the DUQ, a binary logistic regression was performed be-
cause >50% of the participants had the minimum value 
on each of the post-intervention assessments. The DUQ 
scores were dichotomized by splitting the sample into 
those participants who obtained the lowest possible score 
(a total score of 8) and participants who scored higher 
(total score >8). Next, a binary logistic regression model 
was run that included group as a predictor variable and 
time since detoxification as the covariate. As a precau-
tionary measure, we determined whether participants 
had experienced increased craving in response to the al-
cohol stimuli. Pre- and post-session craving scores were 
then averaged across sessions and compared using confi-
dence intervals.
Sustained Effects
Analysis for the TLFB was conducted as described for 
the 4-month time point. Differences between the TAU 
and NFT groups were assessed using ANCOVAs for each 
of the follow-up time points for the HADS, BDI, OCDS, 
alcohol Stroop, and POMS (8 and 12 months). Treatment 
(NFT and TAU) was the between-group factor, and base-
line demographic variables (age, gender, and IQ) were 
included as covariates. For the DUQ, binary logistic re-
gression was performed as described earlier.
Preprocessing the Physiological Data
For each scan, concurrent physiological data were pro-
cessed using an in-house code to generate predictors of 
cardiac and respiratory noise [18–20]. Furthermore, the 
PETCO2 data were used as a predictor of fluctuations in 
arterial CO2 concentration, which is known to modulate 
the BOLD signal. Predictors were demeaned and con-
volved with their respective hemodynamic response 
function.
Off-Line Analysis of MRI Data
(f)MRI Data Preprocessing
Anatomical images were corrected for spatial inten-
sity inhomogeneity and subsequently normalized into 
Montreal Neurological Institute (MNI) stereotactic 
space. Functional data were temporal high-pass filtered 
(GLM Fourier) with 2 cycles, 3D motion correction 
with trilinear estimation and sinc interpolation, linear 
trend removal, and slice scan time correction with cubic 
spline interpolation. For whole-brain analysis, 3D spa-
tial smoothing with a Gaussian filter of 6.00 mm was 
applied. The fMRI data and regions of interest defined 
in 2D space were interpolated into 3D space using 
boundary-based registration and normalized into MNI 
space. All processing steps were performed using Bra-
inVoyager 21.2 (Brain Innovation, Maastricht, the 
Netherlands).
Whole-Brain Analysis
A group random-effects GLM was calculated for each 
localizer task separately, including the types of image (al-
cohol/alternative goals or neutral), 6 motion parameters, 
and predictors of physiological noise as confounding pre-
dictors to estimate beta values. We employed a one-way, 
within-participants design with type of image (alcohol/
alternative goals or neutral) as the factor. Subsequently, 
alcohol/alternative goal-related images were contrasted 
with neutral images, and whole-brain maps were cluster 
corrected using Monte-Carlo simulations at a threshold 
of p = 0.001. Additionally, the overall distribution of the 
neurofeedback target regions across participants was vi-
sualized to provide an overview on the main source of the 
neurofeedback information (see online suppl. material 1; 
see www.karger.com/doi/10.1159/000513448 for all on-
line suppl. material).
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ROI Activation
Mean ROI activation (beta values) from the target ar-
eas in comparison to baseline was averaged across neuro-
feedback sessions within participants, separately for the 2 
types of neurofeedback (alcohol and alternative goals, i.e., 
neurofeedback downregulation and upregulation) and 
task (neurofeedback or mirror run [passive viewing]). Ef-
fects of the neurofeedback were tested using paired t tests, 
by comparing mean activation during neurofeedback 
with mean activation during mirror runs, separately for 
alcohol neurofeedback and alternative goal neurofeed-
back. For each individual, neurofeedback success was de-
fined as lower (alcohol condition)/or higher (alternative 
goal condition) mean activation during neurofeedback 
runs compared to mirror runs.
Relationship between ROI Activation and Behavioral 
Outcome Measures (Exploratory)
To explore whether self-regulation performance during 
the neurofeedback intervention was related to changes in 
drinking behavior, overall self-regulation performance was 
compared between dichotomized groups of participants 
showing high/low outcomes on the TLFB% of days absti-
nent and on the DUQ scores. TLFB amount of alcohol per 
day and % days of heavy drinking were not included be-
cause they would have been redundant. Because all of the 
abstinent participants had not, of course, consumed any al-
cohol and had not engaged in any heavy drinking, the di-
chotomized post-intervention values were identical.
First, an overall marker of self-regulation performance 
was created by averaging self-regulation performance dur-
ing alternative goal neurofeedback (mean beta [neurofeed-
back] – mean beta [mirror] of alternative goal sessions, 
weighted by 1/3) with performance during alcohol neuro-
feedback (mean beta [neurofeedback] – mean beta [mirror] 
of alcohol sessions, weighted by 2/3). Weighting reflected 
the performed number of NFT sessions for each condition, 
that is, 2/6 or 4/6 sessions, respectively. Second, to explore 
the relationship between drinking behavior (TLFB)/crav-
ing (DUQ) and overall neurofeedback performance, 
weighted average scores were descriptively explored by 
comparing mean performance between dichotomized 
groups (low/high values on the respective variable).
Results
Psychological Markers
Analysis on psychological markers could be performed 
for all measures and measurement time points; not all 
data points were available for all participants due to miss-
ing responses/measurement errors.
Baseline Measures
Baseline demographics were in line with expected de-
mographics of the population: mean age = 45.8 years, 
SD = 9.9 (NFT mean = 45 years [SD = 9.9], control = 46 
years [SD = 10.1]), gender: 69% male, 36 males (NFT = 
60% male [15 males], control = 78% male [21 males]). 
Time since detoxification at baseline was weighted over 
the whole sample: 1–3 months: n = 25 (48.0%), 3–6 
months: 27 (51.9%); within groups: NFT 1–3 months: 
n = 12 (48.0%), 3–6 months: 13 (52.0%); and control 1–3 
months: n = 13 (48.1), 3–6 months: 14 (51.9). Baseline 
scores for outcome measures showed no pronounced 
group differences (Table 1).
Primary Outcome Measures
Across all dichotomized markers of drinking behavior 
(TLFB scores) at the post-intervention (4-month) assess-
ment, members of the neurofeedback group nominally 
showed lower alcohol consumption but with wide confi-
dence intervals of the odds ratio that included 1 (Table 2 
includes all patients who participated in the primary and 
secondary outcome assessments). These tendencies were 
also present in the undichotomized means for all of the 
measures, except for the amount of alcohol consumed per 
day (TLFB-amt/day), which showed a nominally higher 
value for the neurofeedback group (Tables 1A, 2). None 
of the group differences on the primary outcome mea-
sures would have been significant at the conventional lev-
el (p < 0.05, with Bonferroni correction for multiple out-
come measures).
Secondary Outcome Measures
Members of the neurofeedback group nominally 
showed a lower probability of having an urge to drink, as 
indicated by the DUQ scores (Table 2). This tendency was 
also pronounced in the undichotomized means for the 
DUQ (Tables 1B, 2). ANCOVA of the OCDS also de-
scriptively showed lower alcohol craving for the neuro-
feedback group (Table 2). Conversely, the alcohol Stroop 
interference was descriptively lower in the TAU group, 
and the affective measures also showed an inconsistent 
pattern (Table 2). None of the group differences on the 
secondary outcome measures would have been signifi-
cant at the conventional level (p < 0.05, with Bonferroni 
correction for multiple outcome measures). The addi-
tional safety measure tracking craving before and after 
the alcohol neurofeedback fRMI runs (via verbal assess-
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ment) did not indicate that craving was induced by the 
alcohol stimuli: mean (before) = 0.21 (SD = 0.25); mean 
(after) = 0.22 (SD = 0.29); mean difference (before minus 
after) = −0.01; 95% CI for the difference: −0.11 to 0.92. 
Considering the skewness of the differences (skewness = 
−2.46, SE = 0.56), a paired-sample sign test was addition-
ally performed and confirmed that the craving scores did 
not increase from pre- to post-assessment (median be-
fore = 0.9, IQR = 0.42; median after = 0.6, IQR = 0.38; 
frequencies: negative differences [before > after] = 4; pos-
itive differences [before < after] = 2; ties = 10).
Accordingly, comparison between the DUQ scores ac-
quired before and after each neurofeedback session did 
not reveal a difference, and craving ratings at both time 
points were low: mean (before) = 11.48 (SD = 4.76); mean 
(after) = 12.55 (SD = 4.80); mean difference (before-af-
ter) = −1.06; 95% CI of the difference: −2.38 to 0.26. Re-
tention was 64% for the neurofeedback group (baseline: 
n = 25, post-intervention: n = 16), and 67% for the TAU 
group (baseline: n = 27, post-intervention: n = 18).
Sustained Effects (8- and 12-Month Follow-Up)
Members of the TAU group compared to members of 
the NFT group showed a tendency toward less alcohol con-
sumption (across all dichotomized markers of drinking be-
havior measured with the TLFB) 8 months after the start of 
the training, but not after 12 months, the confidence inter-
vals included 0 (Table 3). This effect was also apparent in 
the group means of undichotomized variables (Table 1A). 
DUQ results for these follow-up time points are reported in 
Table 3 for the dichotomized values and in Table 1B for the 
undichotomized group means. ANCOVA results for the 
post-intervention time points are shown in Table 3, and the 
descriptive values for the respective secondary outcome 
measures are shown in Table 1B (craving-related measures) 
and Table 1C (mood-related measures).
Table 2. Post-intervention group differences
Primary outcome measures
regression analysis
Exp(B) 95% CI for Exp(B) Δ mean 
(NFT-TAU)lower upper
% abstinent 1.10 0.26 4.65
Incl. detox 1.11 0.26 4.70 4.00
Amount per day 0.91 0.22 3.84
Incl. detox 0.90 0.21 3.83 2.10
% heavy drinking 0.91 0.22 3.84
Incl. detox 0.90 0.21 3.83 −3.80
Secondary outcome measures
regression analysis
Exp(B) 95% CI for Exp(B) or F Δ mean 
(NFT-TAU)lower upper
DUQ 0.29 0.07 1.20
Incl. detox 0.29 0.07 1.23 −4.24
ANCOVA F, η2p lower upper Δ EMM 
(NFT-TAU)
OCDS obsessive subscale F(1, 27) = 1.62, η2p = 0.06 −3.83 0.89 −1.46
OCDS compulsive subscale F(1, 27) = 1.90, η2p = 0.07 −6.57 1.28 −2.64
HADS depression F(1, 27) = 0.17, η2p = 0.01 −3.19 2.12 −0.53
HADS anxiety F(1, 27) = 0.20, η2p = 0.01 −1.97 3.08 0.55
Alcohol Stroop F(1, 22) = 0.53, η2p = 0.02 −37.47 77.91 20.22
POMS (TMD) F(1, 27) = 0.21, η2p = 0.01 −18.11 28.39 5.13
BDI F(1, 27) = 2.07, η2p = 0.07 −12.29 2.16 −5.06
In regression analysis, probability is predicted for being a member of the neurofeedback group. TAU, 
treatment-as-usual; NFT, neurofeedback training; DUQ, Drinking Urge Questionnaire; OCDS, Obsessive 
Compulsive Drinking Scale; HADS, Hospital Anxiety and Depression Scale; POMS, Profile of Mood States; BDI, 
Beck Depression Inventory.






Whole-brain analysis of the localizer data (Fig. 2) re-
vealed pronounced activation for alcohol > neutral in the 
reward system during the alcohol localizer, with signifi-
cant activation in the right anterior cingulate cortex, the 
bilateral anterior insula, and bilateral striatum. There was 
also activation in the bilateral ventrolateral PFC (vLPFC), 
the right premotor cortex, and the posterior cingulate 
cortex. For the alternative goal localizer, activation was 
Table 3. Analysis of sustained effects
Secondary outcome measures Exp(B) 95% CI for Exp(B) Δ mean (NFT-TAU)
time point regression analysis lower upper
8 months % abstinent 0.30 0.05 1.92
Incl. detox 0.27 0.04 1.81 −6.90
12 months % abstinent 1.33 0.23 7.74
Incl. detox 1.16 0.19 7.11 0.88
8 months Amount per day 3.33 0.52 21.28
Incl. detox 3.70 0.55 24.83 4.90
12 months Amount per day 0.75 0.13 4.36
Incl. detox 0.87 0.14 5.32 −0.20
8 months % heavy drinking 2.40 0.36 15.94
Incl. detox 2.45 0.36 16.60 4.59
12 months % heavy drinking 0.75 0.13 4.36
Incl. detox 0.87 0.14 5.32 −0.80
8 months DUQ 1.20 0.25 5.84
Incl. detox 1.35 0.26 6.97 3.19
12 months DUQ 3.33 0.60 18.54
Incl. detox 2.81 0.47 16.92 −0.12
ANCOVA F, η2p lower upper Δ EMM (NFT-TAU)
8 months OCDS obsessive subscale F(1, 18) = 1.44, η2p = 0.07 −1.38 5.08 1.85
12 months F(1, 19) = 0.44, η2p = 0.02 −5.99 3.12 −1.43
8 months OCDS compulsive subscale F(1, 18) = 2.37, η2p = 0.12 −1.03 6.69 2.83
12 months F(1, 19) = 0.47, η2p = 0.02 −6.38 5.18 −0.59
8 months HADS depression F(1, 19) = 3.78, η2p = 0.17 −0.18 4.92 2.37
12 months F(1, 18) = 0.23, η2p = 0.01 −1.93 3.07 0.57
8 months HADS anxiety F(1, 19) = 1.05, η2p = 0.05 −1.62 0.71 1.55
12 months F(1, 18) = 0.91, η2p = 0.05 −1.35 3.60 1.13
8 months Alcohol Stroop F(1, 17) = 1.62, η2p = 0.09 −88.77 21.95 −33.41
12 months F(1, 16) = 1.68, η2p = 0.10 −23.15 96.07 36.46
8 months POMS (TMD) F(1, 18) = 4.00, η2p = 0.18 −1.11 45.37 22.13
12 months F(1, 18) = 1.10, η2p = 0.06 −9.08 27.14 9.03
8 months BDI F(1, 20) = 1.79, η2p = 0.08 −2.28 10.50 4.11
12 months F(1, 17) = 1.49, η2p = 0.08 −10.68 2.86 −3.91
In regression analysis, probability is predicted for being a member of the neurofeedback group. TAU, treatment-as-usual; NFT, 
neurofeedback training; DUQ, Drinking Urge Questionnaire; OCDS, Obsessive Compulsive Drinking Scale; HADS, Hospital Anxiety 
and Depression Scale; POMS, Profile of Mood States; BDI, Beck Depression Inventory.
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present only in cortical areas, that is, the bilateral vLPFC 
and the bilateral visual associative cortex. Activation clus-
ters for both of the localizers overlapped in the left vLPFC.
ROI Activation
There was a trend for a difference between alcohol 
neurofeedback (mean betas across all sessions = 0.03, 
SD = 0.12) and alcohol mirror feedback (mean beta = 
0.09, SD = 0.16); t(15) = −1.93, p = 0.07, EMM differ- 
ence = −0.06 (95% CI −0.131 to 0.004) (Fig. 3a). Twelve 
of the 16 neurofeedback participants achieved lower 
mean activation during alcohol neurofeedback than dur-
ing alcohol mirror feedback. There was a nominal, but 
nonsignificant, difference between alternative goal neu-
rofeedback (mean = 0.04, SD = 0.12) and alternative goal 
mirror feedback (mean = 0.003, SD = 0.15); t(15) = 0.84, 
p = 0.4, EMM difference = −0.03 (95% CI −0.052 to 0.120) 
(Fig.  3b). Ten of the 16 neurofeedback participants 
achieved higher mean activation during alternative goal 
neurofeedback than during alternative goal mirror feed-
back.
Eight of the 16 participants were successful at self-reg-
ulation during both neurofeedback conditions (increased 
activation for alternative goals and decreased activation 
in response to alcohol stimuli during neurofeedback 
compared to mirror feedback). Six participants showed 
moderate performance, that is, successful regulation in 




















4.07 t(15) 10.47 4.07 t(15) 9.56
Overlap
p < 0.001, cluster corrected
Fig. 2. Whole-brain activation (RFX results) across all sessions for the alcohol cue localizer (red/yellow) and al-
ternative life goal localizer (green/mint). Activation maps are displayed on the average brain of all participants. 
aINS, anterior insula; ACC, anterior cingulate cortex; AV, visual associative areas; vLPFC, ventrolateral prefron-
tal cortex, PM, premotor cortex; PO, pars opercularis; PT, pars triangularis; STR, striatum; PCC, posterior cin-
gulate cortex.




neurofeedback and 2 during alternative goal neurofeed-
back). Two of the participants were not able to modulate 
the signal in either condition. (For distribution of the 
ROIs used as neurofeedback targets, see online suppl. ma-
terial 1.) Individual differences in training success were 
not driven by training with different scanner types (par-
ticipants with successful alcohol NFT: GE [n = 3.5]: 2.5, 
Siemens [n = 12.5]: 9.5 [1 participant performed half of 
the alcohol NFT training with each scanner]; positive 
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Fig. 3. Self-regulation performance and relationship to measures 
of craving/drinking behavior. a, b Group mean ROI activation 
(beta values, left) and self-regulation performance of individual 
participants (difference between ROI activation during neurofeed-
back and ROI activation during mirror feedback, right) for both 
training types. Error bars indicate standard errors. c Relationship 
between drinking behavior/craving and overall neurofeedback 
performance. Mean neurofeedback performance separated be-
tween participants showing high values (turquoise) or low values 
(purple) of dichotomized TLFB/DUQ scores. Positive difference 
values (red line) indicate that high-performing participants 
showed desirable outcomes (lower > higher for DUQ; higher > 
lower for abstinence). Error terms indicate standard deviations. 
DUQ, Drinking Urge Questionnaire; TLFB, Timeline Followback.
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Relationship between ROI Activation and Behavioral 
Outcome Measures (Exploratory)
Overall, desirable outcomes (higher TLFB abstinence 
and lower urges to drink, DUQ) were associated with bet-
ter neurofeedback performance (Fig.  3c). Across the 3 
measures, this relationship was strongest at the post-in-
tervention time point (highest difference in neurofeed-
back performance between those with low and those with 
high scores at month 4) and decreased during the follow-
up period. Whereas drinking behavior at baseline (TLFB 
scores) appeared to be unrelated to neurofeedback per-
formance, participants with lower drinking urges at base-
line also showed overall better neurofeedback perfor-
mance. Stratification of neurofeedback results into par-
ticipants who remained abstinent until the 
post-intervention time point and participants who re-
lapsed was in accordance with these findings for alcohol 
neurofeedback (mean difference neurofeedback > mirror 
runs abstinent patients (n = 11): mean = −0.08, SD = 0.12; 
non-abstinent patients (n = 5): mean = −0.03, SD = 0.15) 
and alternative goal neurofeedback (mean difference 
neurofeedback > mirror runs abstinent patients (n = 11): 
mean = 0.07, SD = 0.13; non-abstinent patients (n = 5): 
mean = −0.04, SD = 0.21).
Adverse Events
There was one serious adverse event (nonlethal over-
dose of paracetamol) in the TAU group, which was re-
ported in accordance with the standard procedures of the 
South East Wales Trials Unit and judged to be unrelated 
to the intervention.
Discussion
Feasibility of fMRI-NFT as a Treatment for Alcohol 
Dependence
The patient retention and MRI data show that fMRI-
based NFT for patients with alcohol dependence is fea-
sible. A retention rate of 64% in the intervention group 
for an intensive intervention running over a 4-week pe-
riod is acceptable for patients with a substance use disor-
der. Analysis of neurofeedback performance showed that 
participants were able to use the feedback as instructed. 
Furthermore, indices of craving acquired during the neu-
rofeedback sessions revealed low overall craving in pa-
tients during the neurofeedback sessions and no signifi-
cant increases from before to after the neurofeedback ses-
sions, suggesting that the craving induction presented 
little risk. The relationship between overall task perfor-
mance and less alcohol consumption and craving suggest 
that during the NFT, clinically relevant processes were 
modulated. However, given the lack of differences in clin-
ical outcomes between the NFT + TAU group and the 
TAU only group, we cannot infer that neurofeedback was 
specifically instrumental in maintaining the high absti-
nence rates observed.
High levels of abstinence post-intervention in both 
groups (11/16 in NFT + TAU group, 12/18 in TAU group) 
and low alcohol consumption in the patients who did 
drink diminished the possibility of detecting group dif-
ferences. The abstinence rate in the TAU group was high-
er than expected from the literature on the long-term ef-
fects of inpatient treatment. Relapse rates have been as 
high as 70–80% by the end of the first year, and they have 
typically been in the range of 40–60% within the first few 
months after treatment [21]. In the present study, there-
fore, patients with a high probability of relapse had al-
ready relapsed when recruitment began, and they were 
not included. Overall, 2 conclusions can therefore be 
drawn from this trial: the NFT was itself feasible, but the 
target population seemed too resilient to benefit from the 
neurofeedback intervention.
Neural Effects
The fMRI results provide further support for the fea-
sibility of NFT to modulate the neural mechanisms of in-
terest. Activation during the localizer procedure indicat-
ed that exposure to the visual stimuli engaged the func-
tionally relevant brain systems (Fig.  2), with strong 
involvement of the reward system and cognitive control 
areas in the lateral prefrontal cortex which was accord-
ingly reflected in the individualized target regions (online 
suppl. Fig. 1, 2). Conceptually, increased cue reactivity of 
the reward/salience system in people with alcohol depen-
dence [22–26] is an attractive target for interventions that 
aim to promote abstinence and reduce craving (see, e.g., 
[27, 28]). Considering the predictive association between 
neural cue reactivity and alcohol consumption [29], tech-
niques aiming to attenuate this hyperactivity thus have 
potential utility as a treatment for alcohol use disorders 
(e.g., [26]). The feasibility of the attenuation through 
NFT, which was demonstrated here for the first time, sup-
ports the utility of adding motivational neurofeedback 
[30] to the toolkit of interventions designed for substance 
use disorders.
Implications for Future Studies
A limitation of the present design was that partici-
pant blinding was not possible. Due to the general prob-




lem of identifying an appropriate control condition for 
neurofeedback [31], controlling for confounds associ-
ated with unblinded designs would require the inclu-
sion of several study arms. Considering the lack of re-
search on neurofeedback for alcohol use disorders, it is 
therefore more economical to first determine whether 
its clinical effects relative to existing treatments justify 
an investment in larger studies. Once a design (either 
alone or in addition to standard care) has been shown 
to be (potentially) superior to standard care, it should 
be tested against active control interventions. Future 
multiarmed studies could include a sham condition in 
a blinded design, in which patients receive predeter-
mined visual stimulation matched with regard to the 
positive feedback provided during neurofeedback, as 
well as self-regulation training without feedback, to 
control for generic effects of self-regulation and place-
bo effects [31, 32]. Considering the results of this study, 
subsequent research should also focus on different pa-
tient target groups for which neurofeedback could be 
more effective. One possibility would be to conduct the 
training immediately after detoxification training, in 
order to prevent relapse in a group that is at the highest 
risk of relapse. Another relevant question is whether 
early-stage problem drinkers could benefit from a neu-
rofeedback intervention. Early-stage problem drinkers 
are far more numerous than dependent drinkers, and a 
neurofeedback intervention could help them moderate 
their drinking before it escalates into dependent drink-
ing. Additionally, as more general individual differenc-
es like psychological traits could also influence how pa-
tients react to the neurofeedback setting, assessments of 
such traits could help individualize subsequent clinical 
trials [33]. In line with this notion, higher alcohol crav-
ing at baseline tended to be associated with lower neu-
rofeedback performance, which appeared not to be the 
case for drinking behavior itself. Although these find-
ings are only descriptive at this point, they support that 
individual differences in craving could indicate how pa-
tients will respond to neurofeedback interventions.
Besides improving the selectivity of neurofeedback 
interventions with regard to the target population, the 
training procedure itself should be optimized. For ex-
ample, additional self-regulation training outside of the 
scanner could be a cost-effective solution. Increasing 
the NFT time itself could also facilitate training effects 
but will require a cost-benefit evaluation. Additionally, 
changes in the neurofeedback procedure itself could 
improve training efficacy, but optimizing this compo-
nent will likely require meta-analytic comparisons be-
tween several trials as the search space for potential 
adaptions is extensive (e.g., neurofeedback could be 
built from mean activation of different regions, connec-
tivity between different regions, or multivariate activa-
tion pattern of different regions). Overall, further stud-
ies are required to determine clinical efficacy and to un-
derstand the influence of placebo effects, individual 
differences, and the generic effects of self-regulation 
trainings.
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